阿立哌唑与利培酮治疗首发女性精神分裂症对照研究  

Comparative analysis between aripiprazole and risperdone in treatment of first-episode female schizophrenia

作　　者：尚晓芳[1] 倪苏琳[1] 周敏[1] 

机构地区：[1]南京医科大学附属脑科医院,江苏南京210029

出　　处：《中国民康医学》2009年第21期2673-2674,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:比较阿立哌唑与利培酮治疗首发女性精神分裂症的疗效及安全性。方法:入组48例服用阿立哌唑治疗的首发女性神分裂症患者,选择与其年龄、病程、受教育年限相匹配、服用利培酮治疗的首发女性精神分裂症患者48例,观察疗程为8周。于治疗前疗后第4、8周采用阳性与阴性症状量表(PANSS)评定患者的疗效,以副反应症状量表(TESS)评定患者的不良反应。结果:治疗第8周末立哌唑组有效率85.4%,利培酮组有效率87.5%,两组间无统计学差异(P>0.05)。两组均有程度不等的不良反应,阿立哌唑组较利培更少引起锥体外系反应、体重增加及内分泌影响。结论:阿立哌唑是一种安全有效的抗精神病药。Objective:To compare the efficacy and adverse events of aripiprazole and risperdone in treatment of first-episode female schizophrenia.Methods:We enrolled 48 first-episode female schizophrenia treated with alipiprazole and 48 first-episode female schizophrenia treated with risperdone and matched with patients in risperdone group in age,ill course,and education year for 8 weeks.Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Side Effect Scale (TESS) were used to evaluate the efficacy and safety,respectively.Results:The response rates were 85.4% and 87.5% for aripiprazole group and risperdone group,respectively. There was no significant difference between the two groups in response rate.There were some adverse effects in patients, with less extra pyramidal symptoms,weight gain and endocrine dysfunction in aripiprazole group compared with risperdone group.Conclusions: Aripiprazole is an effective and safe antipsychotic drug,especially for the treatment of first-episode female schizophrenia.

关 键 词：阿立哌唑 利培酮 女性精神分裂症 首发 

分 类 号：R749.3[医药卫生—神经病学与精神病学]